CY1109347T1 - Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης - Google Patents
Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονηςInfo
- Publication number
- CY1109347T1 CY1109347T1 CY20091100900T CY091100900T CY1109347T1 CY 1109347 T1 CY1109347 T1 CY 1109347T1 CY 20091100900 T CY20091100900 T CY 20091100900T CY 091100900 T CY091100900 T CY 091100900T CY 1109347 T1 CY1109347 T1 CY 1109347T1
- Authority
- CY
- Cyprus
- Prior art keywords
- signal transducer
- combination consisting
- combination
- derivative
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση αφορά έναν συνδυασμό που αποτελείται από (α) έναν αναστολέα μεταλλαγής σήματος που επιλέγεται από έναν αναστολέα κινάσης τυροσίνης υποδοχέα PDGF (παράγοντας ανάπτυξης που προέρχεται από τα αιμοπετάλια) και ένα ενεργό συστατικό στοιχείο που μειώνει τη δραστηριότητα του επιδερμικού αυξητικού παράγοντα (EGF) ένα παράγωγο εποθιλόνης του τύπου (I) στην οποία ένωση το Α δηλώνει το Ο ή το NRn όπου το Rn είναι υδρογόνο ή κάτω αλκύλιο, το R είναι υδρογόνο ή κάτω αλκύλιο, και το Ζ είναι Ο ή ένας δεσμός και προαιρετικά τουλάχιστον έναν φαρμακευτικά αποδεκτό φορέα για ταυτόχρονη, ξεχωριστή ή συνεπαγόμενη χρήση, πιο συγκεκριμένα, για την καθυστέρηση της εξέλιξης μιας πολλαπλασιαστικής ασθένειας ή για τη θεραπεία αυτής, μια φαρμακευτική ένωση που περιλαμβάνει τον εν λόγω συνδυασμό, η χρήση του εν λόγω συνδυασμού για την παρασκευή ενός φαρμάκου για την καθυστέρηση της εξέλιξης ή για τη θεραπεία μιας πολλαπλασιαστικής ασθένειας, ένα εμπορικό πακέτο ή προϊόν που αποτελείται από τον εν λόγω συνδυασμό ως συνδυασμένο παρασκεύασμα για ταυτόχρονη, ξεχωριστή ή συνεπαγόμενη χρήση, και τον εν λόγω συνδυασμό για χρήση σε μια μέθοδο θεραπείας ενός θερμόαιμου θηλαστικού, ιδιαίτερα του ανθρώπου.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0104840.4A GB0104840D0 (en) | 2001-02-27 | 2001-02-27 | Use of organic compounds |
US33904001P | 2001-10-30 | 2001-10-30 | |
EP02744903A EP1385522B1 (en) | 2001-02-27 | 2002-02-26 | Combination comprising a signal transduction inhibitor and an epothilone derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109347T1 true CY1109347T1 (el) | 2014-07-02 |
Family
ID=26245767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100900T CY1109347T1 (el) | 2001-02-27 | 2009-08-28 | Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης |
Country Status (23)
Country | Link |
---|---|
US (1) | US7723339B2 (el) |
EP (1) | EP1385522B1 (el) |
JP (1) | JP4499359B2 (el) |
KR (1) | KR100848197B1 (el) |
CN (1) | CN1511036B (el) |
AT (1) | ATE434438T1 (el) |
AU (1) | AU2002308218B2 (el) |
BR (1) | BR0207649A (el) |
CA (1) | CA2439268C (el) |
CY (1) | CY1109347T1 (el) |
DE (1) | DE60232719D1 (el) |
DK (1) | DK1385522T3 (el) |
ES (1) | ES2326264T3 (el) |
HK (1) | HK1062266A1 (el) |
IL (2) | IL157466A0 (el) |
MX (1) | MXPA03007729A (el) |
NO (1) | NO325416B1 (el) |
NZ (1) | NZ527764A (el) |
PL (1) | PL207197B1 (el) |
PT (1) | PT1385522E (el) |
RU (1) | RU2313345C2 (el) |
SK (1) | SK287489B6 (el) |
WO (1) | WO2002067941A2 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4579351B2 (ja) | 1996-12-03 | 2010-11-10 | スローン−ケッタリング インスティトュート フォア キャンサー リサーチ | エポチロンの合成とその中間体及びその類似物並びにその使用 |
SK11082003A3 (sk) | 2001-03-14 | 2004-08-03 | Bristol-Myers Squibb Company | Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení |
EP1704863A3 (en) * | 2001-05-16 | 2010-11-24 | Novartis AG | Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent |
JP4477303B2 (ja) * | 2001-05-16 | 2010-06-09 | ノバルティス アーゲー | N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤 |
AU2002349013A1 (en) * | 2001-10-29 | 2003-05-12 | Novartis Ag | Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
DK1767535T3 (da) | 2002-08-23 | 2010-04-12 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse |
US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
JO2596B1 (en) * | 2004-11-30 | 2011-02-27 | نوفارتيس ايه جي | Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses |
US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
EP2634252B1 (en) | 2005-02-11 | 2018-12-19 | University of Southern California | Method of expressing proteins with disulfide bridges |
EP2029156A4 (en) * | 2006-05-01 | 2010-07-21 | Univ Southern California | POLY THERAPY FOR TREATING CANCER |
WO2010056901A2 (en) | 2008-11-13 | 2010-05-20 | University Of Southern California | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
CN105797168A (zh) | 2010-05-18 | 2016-07-27 | 天蓝制药公司 | 用于治疗自身免疫性疾病或其它疾病的组合物和方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
TW225528B (el) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
HUP9900330A3 (en) * | 1995-07-06 | 2001-08-28 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
EP1367057B1 (de) | 1996-11-18 | 2008-09-17 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone E und F |
CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
WO2000000485A1 (de) * | 1998-06-30 | 2000-01-06 | Schering Aktiengesellschaft | Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung |
EE200100422A (et) * | 1999-02-11 | 2002-12-16 | Schering Aktiengesellschaft | Epotilooni derivaadid, nende valmistamismeetod jafarmatseutiline kasutamine |
DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
-
2002
- 2002-02-26 PT PT02744903T patent/PT1385522E/pt unknown
- 2002-02-26 CA CA002439268A patent/CA2439268C/en not_active Expired - Fee Related
- 2002-02-26 WO PCT/EP2002/002049 patent/WO2002067941A2/en active IP Right Grant
- 2002-02-26 NZ NZ527764A patent/NZ527764A/en not_active IP Right Cessation
- 2002-02-26 AU AU2002308218A patent/AU2002308218B2/en not_active Ceased
- 2002-02-26 PL PL363288A patent/PL207197B1/pl not_active IP Right Cessation
- 2002-02-26 AT AT02744903T patent/ATE434438T1/de active
- 2002-02-26 DK DK02744903T patent/DK1385522T3/da active
- 2002-02-26 MX MXPA03007729A patent/MXPA03007729A/es active IP Right Grant
- 2002-02-26 ES ES02744903T patent/ES2326264T3/es not_active Expired - Lifetime
- 2002-02-26 BR BR0207649-7A patent/BR0207649A/pt not_active Application Discontinuation
- 2002-02-26 US US10/469,367 patent/US7723339B2/en not_active Expired - Fee Related
- 2002-02-26 RU RU2003127392/15A patent/RU2313345C2/ru not_active IP Right Cessation
- 2002-02-26 EP EP02744903A patent/EP1385522B1/en not_active Expired - Lifetime
- 2002-02-26 DE DE60232719T patent/DE60232719D1/de not_active Expired - Lifetime
- 2002-02-26 SK SK1071-2003A patent/SK287489B6/sk not_active IP Right Cessation
- 2002-02-26 CN CN028056086A patent/CN1511036B/zh not_active Expired - Fee Related
- 2002-02-26 IL IL15746602A patent/IL157466A0/xx unknown
- 2002-02-26 KR KR1020037011205A patent/KR100848197B1/ko not_active IP Right Cessation
- 2002-02-26 JP JP2002567308A patent/JP4499359B2/ja not_active Expired - Fee Related
-
2003
- 2003-08-18 IL IL157466A patent/IL157466A/en not_active IP Right Cessation
- 2003-08-25 NO NO20033769A patent/NO325416B1/no not_active IP Right Cessation
-
2004
- 2004-07-15 HK HK04105220.7A patent/HK1062266A1/xx not_active IP Right Cessation
-
2009
- 2009-08-28 CY CY20091100900T patent/CY1109347T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109347T1 (el) | Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης | |
PL371466A1 (en) | N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents | |
NO20076323L (no) | Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat | |
IL176070A0 (en) | COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF | |
BR0314112A (pt) | Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia | |
CY2008010I2 (el) | Ενωσεις που περιλαμβανουν αναστολεις διπεπτυδυλοπεπτιδασης-iv και αντιδιαβητικους παραγοντες | |
CY1110385T1 (el) | Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης | |
DE10196382T1 (de) | Halbleiterchip und Halbleitervorrichtung, für die der Halbleiterchip verwendet wird | |
NO20041582L (no) | Antistoffinhibitorer av GDF-8 og anvendelse derav | |
NO20031833D0 (no) | Behandling av gastrointestinale stromatumorer | |
NO20045434L (no) | En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom | |
EE200300041A (et) | Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid | |
DE60308337D1 (de) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide zur behandlung von ang-ii vermittelt krankheiten | |
ATE289306T1 (de) | N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen | |
DE10204822B8 (de) | Eingabe-/Ausgabeleitungs-Abtastverstärker eines Halbleiterspeicherbauelementes | |
DE60332862D1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen | |
NO20023956D0 (no) | Priperidin- og piperazinsubstituerte N-hydroksyformamider som inhibitorer av metalloproteinaser | |
DE60204791D1 (de) | Synthese von 4-(piperidyl) (2-pyridyl)methanon-(e)-o-methyloxim und seinen salzen | |
EE200000638A (et) | 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm | |
ATE348615T1 (de) | 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit | |
DK1353906T3 (da) | Fremgangsmåde til fremstilling af (3-cyano-1H-indol-7-yl)(4-(4-fluorphenetyl)piperazin-1-yl)-methanon og salte deraf | |
SI1436282T1 (en) | Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts |